---
title: "LifeSci Capital Sticks to Their Buy Rating for Revolution Medicines (RVMD)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285825734.md"
description: "LifeSci Capital analyst Charles Zhu has reaffirmed a Buy rating for Revolution Medicines (RVMD), setting a price target of $263.00. Zhu, who specializes in the Healthcare sector, has an average return of 22.8% and a success rate of 56.59% on his stock recommendations. Previously, Piper Sandler also maintained a Buy rating for RVMD with a price target of $172.00."
datetime: "2026-05-10T01:56:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285825734.md)
  - [en](https://longbridge.com/en/news/285825734.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285825734.md)
---

# LifeSci Capital Sticks to Their Buy Rating for Revolution Medicines (RVMD)

In a report released yesterday, Charles Zhu from LifeSci Capital maintained a Buy rating on Revolution Medicines, with a price target of $263.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Zhu covers the Healthcare sector, focusing on stocks such as IDEAYA Biosciences, Revolution Medicines, and Compass Therapeutics. According to TipRanks, Zhu has an average return of 22.8% and a 56.59% success rate on recommended stocks.

In a report released on May 7, Piper Sandler also maintained a Buy rating on the stock with a $172.00 price target.

### Related Stocks

- [RVMD.US](https://longbridge.com/en/quote/RVMD.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IDYA.US](https://longbridge.com/en/quote/IDYA.US.md)
- [CMPX.US](https://longbridge.com/en/quote/CMPX.US.md)
- [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md)
- [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md)

## Related News & Research

- [Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report](https://longbridge.com/en/news/286590889.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [US Cancer Clinics Rush to Access Revolutionary Pancreatic Cancer Drug Daraxonrasib](https://longbridge.com/en/news/286405546.md)
- [US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug](https://longbridge.com/en/news/286394551.md)
- [A Look At Revolution Medicines (RVMD) Valuation After Daraxonrasib Expanded Access Approval](https://longbridge.com/en/news/285222043.md)